Analyzing enVVeno Medical (NASDAQ:NVNO) & CVRx (NASDAQ:CVRX)

enVVeno Medical (NASDAQ:NVNO) and CVRx (NASDAQ:CVRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership and profitability.

Institutional and Insider Ownership

34.7% of enVVeno Medical shares are owned by institutional investors. Comparatively, 75.3% of CVRx shares are owned by institutional investors. 17.0% of enVVeno Medical shares are owned by insiders. Comparatively, 18.9% of CVRx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

enVVeno Medical has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, CVRx has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for enVVeno Medical and CVRx, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enVVeno Medical	0	0	0	0	N/A
CVRx	0	2	4	0	2.67

CVRx has a consensus price target of $13.60, suggesting a potential upside of 39.63%. Given CVRx’s higher probable upside, analysts clearly believe CVRx is more favorable than enVVeno Medical.

Profitability

This table compares enVVeno Medical and CVRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
enVVeno Medical	N/A	-54.24%	-50.69%
CVRx	-122.52%	-72.51%	-49.78%

Valuation & Earnings

This table compares enVVeno Medical and CVRx’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enVVeno Medical	N/A	N/A	-$23.52 million	($1.66)	-3.31
CVRx	$44.39 million	4.74	-$41.20 million	($2.47)	-3.94

enVVeno Medical has higher earnings, but lower revenue than CVRx. CVRx is trading at a lower price-to-earnings ratio than enVVeno Medical, indicating that it is currently the more affordable of the two stocks.

Summary

CVRx beats enVVeno Medical on 7 of the 12 factors compared between the two stocks.

About enVVeno Medical

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

About CVRx

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.